Inherently Controlled Magnetic Bearing Rotary Blood Pump

描述（由申请人提供）：本项目第二阶段的目标是 展示了完全植入式旋转心室辅助系统的原型 设备（VAD）。该泵采用先进的三维磁力 在第一阶段期间演示了转子的悬挂。该轴承系统 既不需要位置传感器，也不需要有源反馈电子器件， 最简单的3-0磁轴承可用于血泵。轴承线圈 形成调谐电感电容电阻（LCR）电路的一部分。正弦 波发生器为线圈供电。转子的运动改变电感， 因此，电路的调谐使得电流流动的变化 总是与运动方向相反。转子位置控制 是轴承结构和埃姆肖固有的吗法律是满意的。一期 证明了这种关节面结构可以是动态稳定的， 功率消耗，并具有足够的刚度来处理外部施加的冲击， 振动载荷在第二阶段，该计划将推进到设计和 开发一个原型植入式旋转VAD和电子包，并执行 体内试验和体外耐久性试验。成功完成将导致 直接进入第三阶段，并最终获得FDA的临床试验批准。 建议的商业应用：心脏病仍然是美国死亡和残疾的主要原因。 在每年死于心脏相关疾病的60万美国人中，大约有3万到6万人可能通过心脏移植得救。 然而，供体心脏的短缺排除了这一点，并刺激了许多机械心脏辅助和替代装置的发展。如果机械辅助泵被证明足够安全可靠，那么它在改善心脏受损患者生活质量方面的潜在用途将大大扩大市场。

Description (provided by applicant): The goal of this Phase II project is to demonstrate the prototype of a fully implantable rotary ventricular assist device (VAD). This pump utilizes the advanced three-dimensional magnetic suspension for the rotor demonstrated during Phase I. This bearing system requires neither position sensors nor active feedback electronics, resulting in the simplest 3-0 magnetic bearing available for blood pumps. The bearing coils form part of a tuned inductance-capacitance-resistance (LCR) circuit. A sine wave generator powers the coil. Motion of the rotor varies the inductance and therefore tuning of the circuit such that changes in electrical current flow always occur to oppose the direction of motion. Control of the rotor position is inherent in the bearing construction and Eamshaw?s Law is satisfied. Phase I demonstrated that this bearing construct can be dynamically stable, low in power consumption, and adequately stiff to handle externally applied shock and vibration loads. During Phase II, the program will advance to design and develop a prototype implantable rotary VAD and electronics package and perform in-vivo tests and in-vitro endurance tests. Successful completion will lead directly to a Phase Ill effort and ultimately FDA approval for clinical trials. PROPOSED COMMERCIAL APPLICATION: Heart disease remains the leading cause of death and disability in the United States. Of the 600,000 Americans who die each year due to heart-related problems, about 30,000 to 60,000 could probably be saved with heart transplants. However, the shortage of donor hearts precludes this, and has stimulated the development of many mechanical heart assist and replacement devices. Should mechanical assist pumps prove sufficiently safe and reliable, the potential use to improve the quality of life for cardiac-impaired patients dramatically expands the market.